Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.. Last reviewed: 19 June 2025 Next review: This guidance will be ...

Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] In development [GID-TA11140] Expected publication date: TBC . Request commenting ...

The aim is to find and treat lung cancers early, before they grow and spread, to improve the chance of survival. Here’s what’s involved.

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

Dr. Jared Weiss explained that radiation for lung cancer may ease symptoms or aim to cure, with newer targeted forms ...

This updated asthma guideline establishes a consistent approach to improving asthma diagnosis and control in adults and ...

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

Medicare covers yearly lung cancer screenings for people with a high risk of developing lung cancer. The eligibility guidelines were expanded in 2022. Original Medicare (parts A and B) and ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

NICE backs NHS use of Roche's Alecensa as first adjuvant therapy for ALK+ NSCLC, and peri-operative use of MSD's Keytruda for all-comer NSCLC patients ...

The National Comprehensive Cancer Network, a coalition of 33 leading U.S. cancer centers,  has rolled out a digital navigator for its clinical practice guidelines. The new tool delivers frequently ...